Navigation Links
Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
Date:4/11/2013

(PRWEB) April 11, 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will be exhibiting and presenting at the 2013 Global Formulation and Drug Delivery Summit in Amsterdam, The Netherlands.

Tony Pigeon, one of Patheon’s scientific experts will be present at the show. Tony is the Senior Manager, Global Science and Technology at Patheon. During his more than 30 year career, he has acquired a considerable degree of experience working with big pharmaceuticals and small biotechs. His diverse experience in the field of drug product development ranges from pre-formulation to process validation for a wide range of dosage forms, including tablets, capsules, semi-solids, sterile solution and suspension products, oral solution and suspension products and aerosols.

Other Patheon representatives will also be available to meet at the Global Formulation and Drug Delivery summit exhibit hall from April 23-24, 2013, showcasing several of Patheon’s key service offerings. Learn more by visiting Patheon’s booth during the conference. To schedule a meeting in advance send an email to events(at)patheon(dot)com.

For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 18 locations, including 14 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10619404.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
3. Patheon to Present at Informex USA
4. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
5. Patheon to Present at 2013 DCAT Week
6. Patheon to Present New Updates in Drug Formulation and Bioavailability
7. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
10. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
11. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, a ... heart failure and type 2 diabetes, announced that ... novel adeno-associated virus (AAV) vector developed in the ... Ph.D., at Stanford University. The company plans to ... gene therapy product pipeline. "Early ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... 2016  Anaconda BioMed S.L., a pre-clinical stage medical ... generation neuro-thrombectomy system for the treatment of Acute Ischemic ... MD to join its Scientific Advisory Board (SAB). The ... of scientific and clinical experts to Anaconda BioMed S.L., ... BRAIN ® to its clinical phase. The SAB ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, ... uBiome is one of just six company finalists in the Health & Medicine ... uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, ...
Breaking Biology Technology:
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
Breaking Biology News(10 mins):